



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/666,068	09/19/2003	Frank Buettner	1/1399	7677	
28501	7590 11/15/2004		EXAM	EXAMINER	
	GER INGELHEIM CORF	DAVIS, I	DAVIS, BRIAN J		
900 RIDGEBURY ROAD P. O. BOX 368 RIDGEFIELD, CT 06877			ART UNIT	PAPER NUMBER	
			1621		
			DATE MAILED: 11/15/2004	4	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Astion Comment	10/666,068	BUETTNER ET AL.				
Office Action Summary	Examiner	Art Unit				
	Brian J. Davis	1621				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPL' THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. & 133)				
Status .						
1) Responsive to communication(s) filed on	_•					
	action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 1-16 is/are pending in the application. 4a) Of the above claim(s) is/are withdrav 5) Claim(s) is/are allowed. 6) Claim(s) 1-9 is/are rejected. 7) Claim(s) 10-16 is/are objected to. 8) Claim(s) are subject to restriction and/or	vn from consideration.					
Application Papers						
9) The specification is objected to by the Examiner						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the o		• •				
Replacement drawing sheet(s) including the correcting 11) The oath or declaration is objected to by the Example 11.						
Priority under 35 U.S.C. § 119		•				
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori application from the International Bureau * See the attached detailed Office action for a list of 	have been received. have been received in Applicatio ty documents have been received (PCT Rule 17.2(a)).	n No d in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary (I	PTO-413)				
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date <u>2/9/04</u>. 	Paper No(s)/Mail Date 5) Notice of Informal Pa 6) Other:	e				

Art Unit: 1621

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 8 and 9 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by ZA 6802425 (CAPLUS abstract). The reference teaches applicant's compounds when R¹=R²=Me and R³=mono substituted (with phenyl or 4-methylphenyl) C₁ alkyl formulated as tablets (a pharmaceutical composition containing an excipient): RN=24008-01-3 and RN=24008-02-4. Claim 9 is included in this rejection as its limitation is intrinsic to the prior art compound. Claims are unpatentable where the prior art process per se of applying the chemical is the same, notwithstanding applicant's different purpose for application of the compound. *In re Kirby*, 40 USPQ 368. This is so because a compound and its properties are inseparable. *In re Papesch*, 315, F.2d 381, 137 USPQ 43 (CCPA 1963).

Claims 1, 8 and 9 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by US 3,567,244, cited by the applicant in the IDS. As outlined above, the reference clearly anticipates the claims because it teaches applicant's compound (example 12 column 11 line 1).

Art Unit: 1621

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over ZA 6802425 (CAPLUS abstract)

Art Unit: 1621

Applicant claims a set of compounds defined by formula I. The dependent claims further narrow the set.

ZA 6802425 teaches an adjacent homolog of applicant's compound when R¹=R²=R³=Me. That prior art compound is RN=24007-97-4 and is formulated as a tablet (a pharmaceutical composition containing an excipient). Adjacent homologs are considered to be obvious absent unexpected results. "Presumption of unpatentability arises against [a] claim directed to [a] composition of matter the adjacent homologue of which is old in [the] art; burden is on applicant to rebut presumption by showing that [the] claimed compound possess unobvious or unexpected beneficial properties not actually possessed by [the] prior art homologue; it is immaterial that [the] prior art homologue may not be recognized or known to be useful for [the] same purpose or to posses [the] same properties as [the] claimed compound...". This is so because: "[C]haracteristics normally possessed by members of homologous series are principally the same, and vary but gradually from member to member; chemists knowing properties of one member [of the] series would in general know what to expect of adjacent members." In re Henze, 85 USPQ 261, 263 (CCPA 1950). Members of a homologous series must possess unexpected properties not possessed by the homologous compounds disclosed in the prior art. In re Hass, 141 F.2d 127, 60 USPQ 548 (CCPA 1980).

Claims 1-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 3,657,244.

Art Unit: 1621

Applicant's claims have been outlined above.

As outlined above, US 3,657,244 teaches, inter alia, an adjacent homolog of applicant's compound when $R^1=R^2=R^3=Me$ (example 14 column 11 line 65).

Allowable Subject Matter

Claims 10-16 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian J. Davis whose telephone number is 571-272-0638. The examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1621

Page 6

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

BRIAN DAVIS

Brian J. Davis November 10, 2004